Semaglutide
FDA ApprovedStrong EvidenceSemaglutide (GLP-1 Receptor Agonist)
An FDA-approved GLP-1 receptor agonist (Ozempic/Wegovy) that reduces appetite and blood glucose — the most clinically validated weight loss peptide.
Half-Life
~1 week (weekly dosing)
Molecular Weight
4113.6 g/mol
Semaglutide is a synthetic analog of GLP-1 (glucagon-like peptide-1), a naturally occurring incretin hormone secreted by intestinal L-cells in response to food intake. Its unique C18 fatty diacid modification enables albumin binding, extending its half-life to approximately one week — enabling convenient weekly subcutaneous dosing. FDA-approved as Ozempic (2017) for type 2 diabetes and cardiovascular risk reduction, Wegovy (2021) for chronic weight management at higher doses, and Rybelsus for oral type 2 diabetes treatment. The SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events in non-diabetic obese adults, expanding its clinical relevance. Note: research peptide semaglutide sold by vendors is not the same as FDA-approved pharmaceutical Ozempic/Wegovy and is not FDA-approved.
Also Known As
Amino Acid Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 fatty diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg
Reconstitution
FDA-approved versions are pre-filled pens. Research peptide: reconstitute with bacteriostatic water; start with low concentration (0.5 mg/mL) for dose precision.
Open Reconstitution Calculator →